SEC / FDA / FTC Regulatory Watch

2026-06-15

SEC/FDA/FTC Regulatory Watch — Week of June 9–15, 2026

The SEC proposes to repeal the 20-year-old trade-through rule (Reg NMS Rule 611) and finalizes FDTA joint data standards; three enforcement cases yield a $3.36B stock fraud complaint against Napster Corp. defendants and final judgments totaling $2.9M. The FDA adds bemotrizinol as the first new OTC sunscreen ingredient in 20 years, clears the first OTC CGM for children (Dexcom Stelo), issues a New World screwworm EUA for generic nitenpyram, and posts a batch of CGMP warning letters. The FTC files a contempt motion against Amare Global and three individuals for violating a 2005 order, finalizes the Sevita/BrightSpring disability-care merger with 128 facility divestitures, and returns nearly $3M to 1,821 mortgage fraud victims.

SEC / FDA / FTC Regulatory Watch

SEC subpoenas, FDA approvals, and FTC pricing deadline — September 1–7, 2026

SEC false adviser filings, FDA approvals, and FTC final orders - August 24-30, 2026

Crypto rulebook, Genglycos, and FTC pricing scrutiny — August 17–23, 2026

SEC fraud docket, FDA animal-drug EUA, and FTC consumer redress (August 10-16, 2026)

SEC accounting unit, FDA's three product actions, and FTC's disparate-impact policy (August 3-9, 2026)

SEC's $152M investor case, FDA's freeze-dried plasma, and FTC's health-data suit (July 27–August 2, 2026)

SEC/FDA/FTC Regulatory Watch: 24-hour trading, food-color rules, and consumer remedies (July 20–26, 2026)

SEC/FDA/FTC Regulatory Watch: E-Delivery, oral PCSK9 approval, and HSR penalties (July 13-19, 2026)

SEC/FDA/FTC Regulatory Watch — Week of June 30-July 6, 2026

SEC/FDA/FTC Regulatory Watch — Week of June 23–29, 2026

SEC, FDA and FTC Watch: Swap-market comments, drug access moves, and merger remedies

SEC/FDA/FTC Regulatory Watch — Week of June 9–15, 2026